opiate abuse MedDRA version: 9.1 Level: LLT Classification code 10039004 Term: Reversal of opiate activity MedDRA version: 9.1 Level: LLT Classification code 10012346 Term: Dependence on opiates
Conditions
Interventions
Trade Name: Emend
Pharmaceutical Form: Capsule, hard
CAS Number: 170729-80-3
Current Sponsor code: Apr
Other descriptive name: APREPITANT
Concentration unit: mg milligram(s)
Concentration type: equal
Sponsors
Karolinska Institutet
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects will be eligible if they are aged 18 – 50 years and have current opiate use Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Subject will not be eligible if they -currently meet criteria for opiate dependence. -have a positive urine screen for opiates -meet criteria for any other substance dependence disorder except nicotine within the last 12 months -have any ongoing prescription medication other than oral contraceptives or hormone replacement -have any serious medical condition which in the judgment of the investigators makes administration of opiates medically inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the NK1 antagonist aprepitant for its ability to block physiological and psychological effects of opiate receptor activation;Secondary Objective: ;Primary end point(s): Subjective psychological responses to opiate challene | — |
Countries
Sweden
Outcome results
None listed